Advertisement

Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer

  • Douglas D. Taylor
    Correspondence
    Corresponding author. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, 511 S. Floyd St., MDR Room 438, University of Louisville School of Medicine, Louisville, KY 40292, USA. Fax: +1 502 852 0881.
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Louisville School of Medicine, Louisville, KY 40292, USA
    Search for articles by this author
  • Cicek Gercel-Taylor
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Louisville School of Medicine, Louisville, KY 40292, USA
    Search for articles by this author
  • Lynn P. Parker
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Louisville School of Medicine, Louisville, KY 40292, USA
    Search for articles by this author

      Abstract

      Objective

      Most ovarian cancers are diagnosed at advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis. Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG.

      Methods

      The diagnostic array utilizes specific exosome-derived antigens to detect reactive IgG in patients' sera. Specific protein targets were isolated by immunoaffinity from exosomes derived from ovarian tumor cell lines. Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer. Immunoreactivity was also compared between exosomal proteins and their recombinant counterparts.

      Results

      Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested). Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease. Reactivity with placental type alkaline phosphatase, TAG 72, survivin, NY-ESO-1, GRP78, and Muc16 (CA125) allowed the differentiation between Stage III/IV and early stage ovarian cancer.

      Conclusions

      The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer. The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers. Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Memarzadeh S.
        • Berek J.S.
        Advances in the management of epithelial ovarian cancer.
        J. Reprod. Med. 2001; 46: 621-629
        • Hoskins W.J.
        Prospective on ovarian cancer: why prevent?.
        J. Cell. Biochem. 1995; 23: 189-199
        • Berek J.S.
        • Schultes B.C.
        • Nicodemus C.F.
        Biologic and immunologic therapies for ovarian cancer.
        J. Clin. Oncol. 2003; 21: 168-174
        • Nossov V.
        • Amneus M.
        • Su F.
        • Lang J.
        • Janco J.M.T.
        • Reddy S.T.
        • et al.
        The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than CA-125.
        Am. J. Obstet. Gynecol. 2008; 199: 215-223
        • Medeiros L.R.
        • Rosa D.D.
        • da Rosa M.I.
        • Bozzetti M.C.
        Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systemic review.
        Eur. J. Obstet., Gynecol. Reprod. Biol. 2009; 142: 99-105
        • Bast R.C.
        • Badgwell D.
        • Lu Z.
        • Marquez R.
        • Rosen D.
        • Liu J.
        • et al.
        New tumor markers: CA125 and beyond.
        Int. J. Gynecol. Cancer. 2005; 15: 274-281
        • Taylor D.D.
        • Gercel-Taylor C.
        Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? (review).
        Oncol. Rep. 1998 Nov–Dec; 5: 1519-1524
        • Draghici S.
        • Chatterjee M.
        • Tainsky M.A.
        Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens.
        Expert Rev. Mol. Diagn. 2005; 5: 735-743
        • Gagnon A.
        • Kim J.H.
        • Schorge J.O.
        • Ye B.
        • Liu B.
        • Hasselblatt K.
        • et al.
        Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
        Clin. Cancer Res. 2008; 14: 764-771
        • Hellstrom I.
        • Hellstrom K.E.
        SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
        Adv. Exp. Med. Biol. 2008; 622: 15-21
        • Bosscher J.R.
        • Gercel-Taylor C.
        • Watkins C.S.
        • Taylor D.D.
        Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients.
        Gynecol. Oncol. 2001; 81: 138-143
        • Gercel-Taylor C.
        • Bazzett L.B.
        • Taylor D.D.
        Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer.
        Gynecol. Oncol. 2001; 81: 71-76
        • Anderson K.S.
        • LaBaer J.
        The sentinel within: exploiting the immune system for cancer biomarkers.
        J. Proteome Res. 2005; 4: 1123-1133
        • Nesterova M.
        • Johnson N.
        • Cheadle C.
        • Cho-Chung Y.S.
        Autoantibody biomarker opens a new gateway for cancer diagnosis.
        Biochim. Biophys. Acta. 2006; 1762: 398-403
        • Vennegoor C.J.
        • Nijman H.W.
        • Drijfhout J.W.
        • Vernie L.
        • Verstraeten R.A.
        • von Mensdorff-Pouilly S.
        • et al.
        Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.
        Cancer Lett. 1997; 116: 93-101
        • Angelopoulou K.
        • Yu H.
        • Bharaj B.
        • Giai M.
        • Diamandis E.P.
        p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer.
        Clin. Biochem. 2000; 33: 53-62
        • Harpio R.
        • Einarsson R.
        S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
        Clin. Biochem. 2004; 37: 512-518
        • Thorpe J.D.
        • Duan X.
        • Forrest R.
        Effects of blood collection conditions on ovarian cancer serum markers.
        PLoS ONE. 2007; 2: e1281
        • Naora H.
        • Yang Y.Q.
        • Montz F.J.
        • et al.
        A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells.
        Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 4060-4065
        • Dummer R.
        • Mittelman A.
        • Fanizzi F.P.
        • Lucchese G.
        • Willers J.
        • Kanduc D.
        Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients.
        Int. J. Cancer. 2004; 111: 720-726
        • Brichory F.
        • Beer D.
        • LeNaour F.
        • Giordano T.
        • Hanash S.
        Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer.
        Cancer Res. 2001; 61: 7908-7912
        • Conroy S.E.
        • Gibson S.L.
        • Brunstrom G.
        • Isenberg D.
        • Luqmani Y.
        • Latchman D.S.
        Autoantibodies to 90kD heat-shock protein in sera of breast cancer patients.
        Lancet. 1995; 345: 126
        • Vlock D.R.
        • Scalise D.
        • Schwartz D.R.
        • et al.
        Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration.
        Cancer Res. 1989; 49: 1361-1365
        • Kutteh W.H.
        • Miller D.S.
        • Mathis J.M.
        Immunologic characterization of tumor markers in human ovarian cancer cell lines.
        J. Soc. Gynecol. Investig. 1996; 3: 216-222
        • Taylor D.D.
        • Homesley H.D.
        • Doellgast G.J.
        Identification of antigenic components recognized by “membrane bound” antibodies from ovarian cancer patients.
        Am. J. Reprod. Immunol. 1984; 6: 179-184
        • Vogl F.D.
        • Frey M.
        • Kreienberg R.
        • Runnebaum I.B.
        Autoimmunity against p53 predicts invasive cancer with poor survival in patients with ovarian mass.
        Br. J. Cancer. 2000; 83: 1338-1343
        • Finn O.J.
        Immune response as a biomarker for cancer detection and a lot more.
        N. Engl. J. Med. 2005; 353: 1288-1290
        • Imai H.
        • Nakano Y.
        • Kiyosawa K.
        • Tan E.M.
        Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma.
        Cancer. 1993; 71: 26-35
        • Imai H.
        • Ochs R.L.
        • Kiyosawa K.
        • Furuta S.
        • Nakamura R.M.
        • Tan E.M.
        Nucleolar antigen and autoantibodies in hepatocellular carcinoma and other malignancies.
        Am. J. Pathol. 1992; 140: 859-870
        • Tang R.
        • Ko M.C.
        • Wang J.Y.
        • Changchien C.R.
        • Chen H.H.
        • Chen J.S.
        • et al.
        Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients.
        Int. J. Cancer. 2001; 94: 859-863
        • Lutz A.M.
        • Willmann J.K.
        • Cochran F.V.
        • Ray P.
        • Gambhir S.S.
        Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.
        PLoS Med. 2008; 5: 1287-1297
        • Manahan K.J.
        • Taylor D.D.
        • Gercel-Taylor C.
        Clonal heterogeneity of p53 mutations in ovarian cancer.
        Int. J. Oncol. 2001; 19: 387-394
        • Gibb R.K.
        • Taylor D.D.
        • Wan T.
        • O'Connor D.M.
        • Doering D.L.
        • Gercel-Taylor C.
        Apoptosis as a measure of chemosensitivity to cisplatin and Taxol therapy in ovarian cancer cell lines.
        Gynecol. Oncol. 1997; 65: 13-22
        • Laemmli U.K.
        Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
        Nature. 1970; 227: 680-685
        • Brown R.
        • Clugston C.
        • Burns P.
        • Edlin A.
        • Vasey P.
        • Vojtesek B.
        • et al.
        Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.
        Int. J. Cancer. 1993; 55: 678-684
        • Marx D.
        • Frey M.
        • Zentgraf H.
        • Adelssen G.
        • Schauer A.
        • Kuhn W.
        • et al.
        Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
        Cancer Detect. Prev. 2001; 25: 117-122
        • Pfreundschuh M.
        Exploitation of the B cell repertoire for the identification of human tumor antigens.
        Cancer Chemother. Pharmacol. 2000; 46: S3-S7
        • Old L.J.
        • Chen Y.T.
        New paths in human cancer serology.
        J. Exp. Med. 1998; 187: 1163-1167
        • Nishikawa H.
        • Tanida K.
        • Ikeda H.
        • Sakakura M.
        • Miyahara Y.
        • Aota T.
        • et al.
        Role of SEREX defined immunogenic wild-type cellular molecules in the development of tumor specific immunity.
        Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 14571-14576
        • Chatterjee M.
        • Wojciechowski J.
        • Tainsky M.A.
        Discovery of antibody biomarkers using protein microarrays of tumor antigens cloned in high throughput.
        Methods Mol. Biol. 2009; 520: 21-38
        • Chatterjee M.
        • Mohapatra S.
        • Ionan A.
        • Bawa G.
        • Ali-Fehmi R.
        • Wang X.
        • et al.
        Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.
        Cancer Res. 2006; 66: 1181-1190
        • Taylor D.D.
        • Doellgast G.J.
        Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography.
        Anal. Biochem. 1979; 98: 53-59
        • Ravanshad M.
        • Sabahi F.
        • Mahboudi F.
        • Roostaee M.H.
        • Forooshani R.S.
        • Kazemnejad A.
        An accurate confirmation of human immunodeficiency virus type 1 (HIV-1) and 2 (HIV-2) infections with a dot blot assay using recombinant p24, gp41, gp120 and gp36 antigens.
        Int. J. Med. Sci. 2004; 1: 193-200